In breast cancer, targeted inhibition of FTO can reduce the production of lactic acid and ATP and inhibit the activities of pyruvate kinase and hexokinase, and lead to the inactivation of AKT, overexpression of FTO can promote the glycolysis ability of tumor cells and the activation of PI3K/AKT pathway 129. This evidence concerns the gene AKT1 and breast cancer.